KR20250008741A - 칸나비노이드 수용체 1 길항제/역작용제 및 이의 용도 - Google Patents
칸나비노이드 수용체 1 길항제/역작용제 및 이의 용도 Download PDFInfo
- Publication number
- KR20250008741A KR20250008741A KR1020247036964A KR20247036964A KR20250008741A KR 20250008741 A KR20250008741 A KR 20250008741A KR 1020247036964 A KR1020247036964 A KR 1020247036964A KR 20247036964 A KR20247036964 A KR 20247036964A KR 20250008741 A KR20250008741 A KR 20250008741A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mmol
- alkyl
- pharmaceutically acceptable
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328611P | 2022-04-07 | 2022-04-07 | |
| US63/328,611 | 2022-04-07 | ||
| US202363439645P | 2023-01-18 | 2023-01-18 | |
| US63/439,645 | 2023-01-18 | ||
| PCT/US2023/017817 WO2023196556A1 (en) | 2022-04-07 | 2023-04-07 | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250008741A true KR20250008741A (ko) | 2025-01-15 |
Family
ID=88243528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247036964A Pending KR20250008741A (ko) | 2022-04-07 | 2023-04-07 | 칸나비노이드 수용체 1 길항제/역작용제 및 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250248973A1 (https=) |
| EP (1) | EP4504179A4 (https=) |
| JP (1) | JP2025512995A (https=) |
| KR (1) | KR20250008741A (https=) |
| CN (1) | CN119325378A (https=) |
| AU (1) | AU2023250955A1 (https=) |
| CA (1) | CA3255170A1 (https=) |
| GB (1) | GB2633943A (https=) |
| IL (1) | IL315945A (https=) |
| MX (1) | MX2024012263A (https=) |
| WO (1) | WO2023196556A1 (https=) |
| ZA (1) | ZA202407552B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025040089A1 (zh) * | 2023-08-21 | 2025-02-27 | 德睿智药(苏州)新药研发有限公司 | 用于选择性调节大麻素cb1功能的新型杂环类化合物 |
| WO2025103493A1 (zh) * | 2023-11-16 | 2025-05-22 | 西藏海思科制药有限公司 | 一种大麻素受体1拮抗剂及其应用 |
| WO2025185689A1 (zh) * | 2024-03-08 | 2025-09-12 | 成都轻胜生物医药科技有限公司 | 吡唑衍生物及其用途 |
| CN118580162A (zh) * | 2024-05-27 | 2024-09-03 | 中国药科大学 | 一种酰肼类化合物及无金属策略促进酰肼类化合物制备的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL363751A1 (en) * | 2001-03-22 | 2004-11-29 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| US8580768B2 (en) * | 2010-11-18 | 2013-11-12 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| KR20150113762A (ko) * | 2014-03-31 | 2015-10-08 | 한미약품 주식회사 | 황 작용기를 포함하는 4,5-다이하이드로-1h-피라졸-3-카복스이미드아마이드 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| EP3109237A1 (en) * | 2015-06-22 | 2016-12-28 | AnaMar AB | Novel 5-ht2 antagonists |
| US12286405B2 (en) * | 2019-05-17 | 2025-04-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase |
-
2023
- 2023-04-07 KR KR1020247036964A patent/KR20250008741A/ko active Pending
- 2023-04-07 EP EP23785417.9A patent/EP4504179A4/en active Pending
- 2023-04-07 US US18/854,216 patent/US20250248973A1/en active Pending
- 2023-04-07 CN CN202380045595.XA patent/CN119325378A/zh active Pending
- 2023-04-07 AU AU2023250955A patent/AU2023250955A1/en active Pending
- 2023-04-07 CA CA3255170A patent/CA3255170A1/en active Pending
- 2023-04-07 IL IL315945A patent/IL315945A/en unknown
- 2023-04-07 GB GB2416413.9A patent/GB2633943A/en active Pending
- 2023-04-07 WO PCT/US2023/017817 patent/WO2023196556A1/en not_active Ceased
- 2023-04-07 JP JP2024559421A patent/JP2025512995A/ja active Pending
-
2024
- 2024-10-03 MX MX2024012263A patent/MX2024012263A/es unknown
- 2024-10-04 ZA ZA2024/07552A patent/ZA202407552B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119325378A (zh) | 2025-01-17 |
| US20250248973A1 (en) | 2025-08-07 |
| GB202416413D0 (en) | 2024-12-25 |
| WO2023196556A1 (en) | 2023-10-12 |
| IL315945A (en) | 2024-11-01 |
| CA3255170A1 (en) | 2023-10-12 |
| AU2023250955A1 (en) | 2024-10-17 |
| GB2633943A (en) | 2025-03-26 |
| MX2024012263A (es) | 2025-01-09 |
| JP2025512995A (ja) | 2025-04-22 |
| EP4504179A1 (en) | 2025-02-12 |
| ZA202407552B (en) | 2025-12-17 |
| EP4504179A4 (en) | 2026-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20250008741A (ko) | 칸나비노이드 수용체 1 길항제/역작용제 및 이의 용도 | |
| CN105008362B (zh) | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物 | |
| CN109863140B (zh) | 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺 | |
| EP3022202B1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| JP5837482B2 (ja) | ピラゾールオキサジアゾール誘導体 | |
| PT1024138E (pt) | Derivados de pirazole | |
| WO2023164050A1 (en) | Compounds as glp-1r agonists | |
| CA3047002A1 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| WO2006080450A1 (ja) | Igf-1r阻害剤 | |
| TW201315727A (zh) | 尿嘧啶衍生物及其醫藥用途 | |
| CN115413279A (zh) | P2x3调节剂 | |
| CN110121341A (zh) | 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲唑衍生物 | |
| KR20210130753A (ko) | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 | |
| AU2017290705A1 (en) | Compounds and compositions for the treatment of cancer | |
| TW202028210A (zh) | 用於治療與apj受體活性相關的病狀的化合物及組成物 | |
| CN105916506A (zh) | 作为tam家族激酶抑制剂的喹唑啉衍生物 | |
| RU2377238C2 (ru) | Производные имидазола, активные в отношении рецептора св1 | |
| CN109641909B (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
| WO2015162452A1 (en) | Substituted pyrazole compounds as cb1 receptor antagonists and uses thereof | |
| JP2007538102A (ja) | 糖尿病の処置に有用な５−アニリノ−４−ヘテロアリールピラゾール誘導体 | |
| HK40122921A (zh) | 大麻素受体1拮抗剂/反向激动剂及其用途 | |
| JP3116256B2 (ja) | （チオ）ウレア誘導体 | |
| WO2026072914A1 (en) | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | |
| CN114846004A (zh) | 新型抗疟药 | |
| CN101243074A (zh) | 杂环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |